相似文献
1
The use of immunosuppressive and cytotoxic drugs in non-malignant disease.
Arch Dis Child. 2000 Sep;83(3):259-64. doi: 10.1136/adc.83.3.259.
2
[Therapy of inflammatory rheumatic diseases: from current practice standards to future].
Internist (Berl). 2001 Feb;42(2):223-32, 234-6. doi: 10.1007/s001080050746.
3
Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity.
Ann Intern Med. 1998 Jul 1;129(1):49-58. doi: 10.7326/0003-4819-129-1-199807010-00012.
4
Practical use of immunosuppressive drugs in autoimmune rheumatic diseases.
Crit Care Med. 1990 Feb;18(2 Suppl):S132-7.
5
[Treatment of pure and primary nephrotic syndromes by immunosuppressive chemotherapy].
Rein Foie. 1966;8:19-30.
6
[Vasculitis in inflammatory-rheumatic diseases--current diagnosis and therapy].
Z Arztl Fortbild (Jena). 1994 Nov;88(11):881-90.
7
[Immunosuppressive therapy in pediatrics].
Wien Med Wochenschr. 1971 Jan 23;121(4):49-53.
8
[Steroids or cytostatics in the juvenile nephrotic syndrome].
Klin Padiatr. 1972 Jul;184(4):241-9.
9
[Immunosuppressive therapy with cytostatic agents in rheumatology].
Rev Esp Reum Enferm Osteoartic. 1969 Oct;13(4):204-14.
10
Vaccination in adults with autoimmune rheumatic diseases.
CMAJ. 2019 Sep 9;191(36):E1005. doi: 10.1503/cmaj.190345.
引用本文的文献
1
The impact of the use of immunosuppressive treatment after an embryo transfer in increasing the rate of live birth.
Front Med (Lausanne). 2023 Jun 27;10:1167876. doi: 10.3389/fmed.2023.1167876. eCollection 2023.
2
Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities.
Adv Sci (Weinh). 2023 Jul;10(20):e2301777. doi: 10.1002/advs.202301777. Epub 2023 May 7.
3
Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory.
Front Immunol. 2022 Oct 10;13:984252. doi: 10.3389/fimmu.2022.984252. eCollection 2022.
4
Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.
Cochrane Database Syst Rev. 2018 Mar 27;3(3):CD012860. doi: 10.1002/14651858.CD012860.pub2.
5
Medium-size-vessel vasculitis.
Pediatr Nephrol. 2010 Sep;25(9):1641-52. doi: 10.1007/s00467-009-1336-1. Epub 2009 Nov 28.
6
Small vessel vasculitis.
Pediatr Nephrol. 2010 Jun;25(6):1025-35. doi: 10.1007/s00467-009-1317-4. Epub 2009 Nov 3.
7
Vasculitis treatment - new therapeutic approaches.
Eur J Pediatr. 2006 Jun;165(6):351-7. doi: 10.1007/s00431-005-0070-3. Epub 2006 Mar 9.
本文引用的文献
1
THE DIAGNOSTIC VALUE OF ANGIOGRAPHIC OBSERVATIONS IN POLYARTERITIS NODOSA. A CASE OF MULTIPLE ANEURYSMS IN THE VISCERAL ORGANS.
Arch Intern Med. 1965 Sep;116:450-4. doi: 10.1001/archinte.1965.03870030130024.
2
The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis.
J Pediatr. 1999 Sep;135(3):316-20. doi: 10.1016/s0022-3476(99)70127-7.
3
Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases.
Ann Intern Med. 1999 Mar 2;130(5):422-6. doi: 10.7326/0003-4819-130-5-199903020-00013.
4
Methotrexate treatment for sarcoid-associated panuveitis.
Ophthalmology. 1999 Jan;106(1):111-8. doi: 10.1016/S0161-6420(99)90011-8.
5
Mycophenolate mofetil in patients with Crohn's disease.
Am J Gastroenterol. 1998 Dec;93(12):2529-32. doi: 10.1111/j.1572-0241.1998.00606.x.
6
Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.
Arthritis Rheum. 1998 Oct;41(10):1835-44. doi: 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q.
7
The use and misuse of classification and diagnostic criteria for complex diseases.
Ann Intern Med. 1998 Sep 1;129(5):417-8. doi: 10.7326/0003-4819-129-5-199809010-00013.
8
Vincristine and focal segmental sclerosis: do we need a multicentre trial?
Pediatr Nephrol. 1998 May;12(4):284-9. doi: 10.1007/s004670050454.
9
Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity.
Ann Intern Med. 1998 Jul 1;129(1):49-58. doi: 10.7326/0003-4819-129-1-199807010-00012.
10
Childhood vasculitis.
Lupus. 1998;7(4):259-65. doi: 10.1191/096120398678920064.
Zotero 插件